Standardization of HER2 testing: results of an international proficiency-testing ring study

This publication has 29 references indexed in Scilit:

• Pathology of borderline HER-2/neu breast carcinoma: a biologically distinct phenotype
  Breast Cancer Research and Treatment, 2006
• Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm
  Laboratory Investigation, 2006
• Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
  New England Journal of Medicine, 2005
• Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group
  Journal of Clinical Oncology, 2005
• Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER‐2 in 426 breast carcinomas from 37 centres
  The Journal of Pathology, 2003
• Current Perspectives on HER2 Testing: A Review of National Testing Guidelines
  Laboratory Investigation, 2003
• Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
  Journal of Clinical Oncology, 2002
• and choice of adjuvant chemotherapy in breast cancer
  Seminars in Oncology, 2001
• Testing for HER2 Status
  Oncology, 2001
• The biology of erbB-2/nue/HER-2 and its role in cancer
  Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1994